Inj pause or tab pause and botroclot drops Uses , mechanism, specific condition, contra indication of these medicines with specific reason
Reading File
Finding Sources
Finding Sources
Searching the Web
Pause injection tablet etamsylate uses mechanism contraindications hemostatic
Searching the Web
Botroclot nasal drops batroxobin hemocoagulase uses mechanism contraindications India
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC7501396
Finding Sources
I now have enough information from both the medical library and web sources to provide a thorough answer. Here it is:
Inj/Tab Pause (Etamsylate) and Botroclot Drops (Hemocoagulase)
Both are hemostatic agents - they stop or reduce bleeding - but through very different mechanisms.
PAUSE (Etamsylate) - Inj / Tab 250 mg / 500 mg
What It Is
Etamsylate (also spelled ethamsylate) is a synthetic hemostatic drug. Marketed as Pause (injection and tablet) and also as Dicynone, Cyclonamine in other markets.
Mechanism of Action
Etamsylate works through 3 complementary pathways:
-
Reduces capillary fragility and permeability - It strengthens the endothelial wall of small blood vessels (capillaries), making them less likely to leak or bleed. This is its primary and most important action.
-
Promotes platelet adhesion - It enhances the stickiness of platelets at the site of vascular injury, facilitating platelet plug formation. It does this by correcting abnormal platelet adhesion without activating systemic coagulation.
-
Inhibits prostaglandin synthesis (PGI2/prostacyclin) - Prostacyclin is a potent vasodilator and platelet aggregation inhibitor. By blocking prostacyclin synthesis, etamsylate allows platelet aggregation to proceed more effectively. This is linked to inhibition of hyaluronidase and prostaglandin biosynthesis.
Important: Etamsylate does NOT affect the coagulation cascade (no effect on PT, aPTT, fibrinogen), does NOT cause vasoconstriction, and does NOT work through antifibrinolysis. It purely acts at the capillary/platelet level.
Uses
| Condition | Reason |
|---|---|
| Menorrhagia (heavy menstrual bleeding) | Most common use - reduces capillary fragility in the uterine lining |
| Postpartum hemorrhage | Adjunct to control capillary ooze after delivery |
| Perioperative/surgical bleeding | Reduces ooze from small vessels during and after surgery |
| Epistaxis (nosebleed) | Reduces capillary fragility in nasal mucosa |
| Hematuria (blood in urine) | Controls bleeding from urinary tract capillaries |
| Gastrointestinal bleeding | Adjunct therapy for capillary-origin GI bleeds |
| Prevention of periventricular/intraventricular hemorrhage (IVH) | In premature very low birth weight neonates - reduces capillary bleeding in the fragile germinal matrix (supported by trials cited in Adams & Victor's Neurology and Creasy & Resnik's Maternal-Fetal Medicine) |
| Retinal hemorrhage | Reduces capillary leak in retinal vessels (e.g., diabetic retinopathy) |
| Dental procedures | Controls capillary oozing during extractions |
Specific Clinical Conditions with Reasoning
- Menorrhagia: Dysfunctional uterine bleeding involves abnormal prostaglandin activity and increased capillary fragility. Etamsylate addresses both by inhibiting prostacyclin and strengthening capillary walls.
- Premature neonatal IVH: The germinal matrix in preterm infants has immature, highly fragile capillaries. Etamsylate reduces capillary fragility and platelet adhesion defects common in premature infants.
- Hematuria: Acts locally on the urinary tract epithelial capillaries without systemic procoagulant risk.
Contraindications
| Contraindication | Specific Reason |
|---|---|
| Hypersensitivity to etamsylate | Risk of anaphylaxis/allergic reaction |
| Thromboembolic disorders (history of DVT, pulmonary embolism, stroke) | Even though etamsylate does not directly activate the clotting cascade, its pro-aggregatory platelet effect can theoretically tip the balance toward clot formation in already hypercoagulable patients |
| Porphyria | Etamsylate is listed as a potentially unsafe drug in porphyria - can precipitate acute porphyric attacks |
| Pregnancy (first trimester) - use with caution | Limited safety data; avoid in the first trimester unless benefit clearly outweighs risk |
| Renal/hepatic impairment | Dose adjustment required; clearance may be reduced |
Lab interference note: Etamsylate (due to its hydroquinone structure) interferes with enzymatic creatinine assays (Jaffe and enzymatic methods), causing falsely elevated serum creatinine readings - an important point for labs (Tietz Textbook of Laboratory Medicine, 7th Ed.).
Dosage (Reference)
- Tablet: 500 mg 3-4 times daily
- Injection (IV/IM): 250-500 mg, repeat as needed every 4-6 hours
- Onset: Rapid (within 1 hour IV, 2-3 hours oral)
BOTROCLOT DROPS / SOLUTION (Hemocoagulase / Batroxobin)
What It Is
Botroclot Topical Solution contains sterile hemocoagulase 0.2 CU (Coagulation Units) + chlorhexidine 0.1% (antiseptic). Hemocoagulase is an enzyme isolated from the venom of the pit viper Bothrops atrox (lancehead snake). The active molecule is Batroxobin (BTX).
It is available as a topical solution (drops/liquid applied directly to wounds) - NOT for IV injection in this formulation.
Mechanism of Action
Hemocoagulase/Batroxobin works by:
-
Thrombin-like (proteolytic) enzyme activity - Batroxobin directly cleaves fibrinogen into fibrin monomers (mimicking thrombin), causing local clot formation at the application site. Unlike thrombin, it cleaves only the A fibrinopeptide from fibrinogen (not B), producing a "soft" fibrin clot.
-
Thromboplastin-like activity - It activates the extrinsic pathway of coagulation locally.
-
Promotes platelet aggregation locally - Enhances platelet clumping at the bleeding site.
-
Chlorhexidine component - Provides antiseptic action, preventing infection at the wound site while hemostasis is being established.
Key point: The clot formed by batroxobin is local only - the drug does not enter the systemic circulation significantly in topical form, so it does not cause systemic thrombosis.
Uses
| Condition | Reason |
|---|---|
| Minor surgical bleeding / dental surgery | Applied topically to the surgical socket or wound to achieve rapid local hemostasis |
| Epistaxis (nosebleeds) | Dropped into the nostril to stop bleeding from nasal capillaries and mucosa |
| Post-extraction dental bleeding | Controls oozing after tooth extractions |
| Lacerations and traumatic wounds | Applied to superficial cuts and wounds |
| Oral/gingival bleeding | Controls bleeding from gums |
| Pulmonary hemorrhage | Injectable form (Botropase) used systemically for lung bleeding |
| Post-operative bleeding (systemic hemocoagulase injection) | Injectable forms control major surgical and traumatic hemorrhage |
| Diabetic wound healing | Emerging evidence shows Botroclot promotes collagen deposition and wound contraction in diabetic wounds (PMC7501396) |
Specific Clinical Conditions with Reasoning
- Dental procedures: The enzyme is applied directly into the extraction socket; it triggers immediate fibrin clot formation locally without disturbing systemic coagulation - safe even in patients who are on anticoagulants for local use.
- Epistaxis: A few drops placed in the nostril directly coagulates bleeding vessels in the nasal mucosa.
- Diabetic wounds: Hemocoagulase promotes early granulation tissue formation and collagen (Type I and III) deposition, aiding wound closure in addition to clot formation.
Contraindications
| Contraindication | Specific Reason |
|---|---|
| Known allergy/hypersensitivity to hemocoagulase or snake venom-derived proteins | Risk of severe anaphylactic reaction - snake venom proteins are potent allergens |
| Disseminated Intravascular Coagulation (DIC) | In DIC, there is already massive uncontrolled fibrin deposition; adding a procoagulant enzyme could worsen consumptive coagulopathy and organ failure |
| History of thrombosis / intravascular clotting | The drug promotes clotting; using it in patients with DVT, PE, arterial thrombosis, or stroke risks extending existing clots or forming new ones |
| Severe renal insufficiency | Accumulation of drug and impaired clearance increases risk of adverse effects |
| Pregnancy | Limited safety data; use only if clearly necessary under medical supervision |
| Children under 12 | Safety not established in pediatric population |
| Not for IV use (topical formulation) | Botroclot Solution is for external use ONLY - intravenous injection of this formulation would cause systemic coagulation and potentially fatal thrombosis |
Quick Comparison Table
| Feature | Pause (Etamsylate) | Botroclot (Hemocoagulase) |
|---|---|---|
| Origin | Synthetic chemical | Snake venom enzyme (Bothrops atrox) |
| Route | IV / IM / Oral | Topical (drops/solution) |
| Primary mechanism | Reduces capillary fragility + inhibits prostacyclin | Direct fibrinogen-to-fibrin conversion (thrombin-like) |
| Effect on coagulation | Does NOT alter PT/aPTT | Promotes local fibrin clot |
| Key use | Menorrhagia, surgical ooze, neonatal IVH | Dental/minor surgical bleeding, epistaxis, wounds |
| Key contraindication | Porphyria, thromboembolic history | DIC, allergy to snake proteins, intravascular thrombosis |
| Antiseptic component | No | Yes (chlorhexidine 0.1%) |
Clinical pearl: Pause (etamsylate) is a systemic hemostatic acting on capillaries and platelets throughout the body, while Botroclot is a local hemostatic that directly triggers clot formation at the site of application. They are not interchangeable and serve different purposes.
This is a shared conversation. Sign in to Orris to start your own chat.